Clinical trial · Interventional
Hypofractionated Imrt (Vmat-Ra) For Elderly Patients With Newly Diagnosed High Grade Glioma
Hypofractionated Imrt (Vmat-Ra) With Temozolomide For Elderly Patients, Unsuitable For Surgery With Newly Diagnosed High Grade Glioma
NCT02099487CI-TRIAL-00022324completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess the effect of IMRT using VMAT rapidarc approach, followed by adjuvant temozolomide on survival and quality of life in elderly, poor performance status patients with newly diagnosed HGG.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiation | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Radiation
- description
- To evaluate safety and feasibility of hypofractionated Intensity Modulated Radiotherapy
- interventionNames
- Radiation: Radiation
Primary outcomes (1)
- measure
- PFS
- timeFrame
- one year
- description
- Progression free survival
Secondary outcomes (1)
- measure
- OS
- timeFrame
- one year
- description
- Overall Survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged ≥ 70 years * Karnosky performance status (KPS) ≤60 * Histologically confirmed HGG after tumor biopsy * GBM * Anaplastic Astrocytoma * Anaplastic Oligoastrocytoma * Anaplastic Oligodendroglioma without IDH1 mutation and no codeletion 1p19q * Estimated survival ≥ 3 months. * Normal liver, Kidney and bone marrow function * Written informed consent Exclusion criteria: * Prior radiation therapy * Other primary cancer Exclusion Criteria: \-
References
Publications (0)
Data not yet available
No reference posted for this study.